Jade Biosciences Business Summary

Jade Biosciences, Inc. (JBIO) is a clinical-stage biotechnology company that operates on a research-and-development-driven business model, primarily generating value through the advancement of its proprietary pipeline of monoclonal antibodies for autoimmune diseases. The company’s primary business segments are centered on its lead therapeutic candidates: JADE101, an anti-APRIL antibody currently in Phase 1 trials for IgA nephropathy, and JADE201, an afucosylated anti-BAFF-R antibody targeting rheumatoid arthritis. JBIO’s competitive strategy leverages high-affinity binding and half-life extension technologies licensed from Paragon Therapeutics to differentiate its assets from existing therapies. In the autoimmune and nephrology landscape, Jade competes directly with firms such as Viking Therapeutics, Xenon Pharmaceuticals, and Arcutis Biotherapeutics, positioning itself as a specialist in B-cell and antibody-mediated biology with a focus on superior pharmacokinetic profiles. Launched in 2024 by Fairmount and Paragon Therapeutics, Jade is led by an executive team with a deep pedigree in biopharmaceutical exits and drug development. Chief Executive Officer Tom Frohlich and Chief Scientific Officer Dr. Andrew King both previously held senior leadership roles at Chinook Therapeutics, where they were instrumental in the company’s $3.2 billion acquisition by Novartis. The leadership team also includes Chief Financial Officer Brad Dahms and General Counsel Elizabeth Balta. Jade is supported by a prominent investor syndicate that includes Frazier Life Sciences, Versant Ventures, Venrock, and Deep Track Capital. Its Board of Directors is chaired by Eric Dobmeier, former CEO of Chinook Therapeutics and executive at Seagen, and includes industry veterans such as Tomas Kiselak and Chris Cain of Fairmount, alongside Lawrence Klein, CEO of Oruka Therapeutics.